|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma显示文摘AIM: To assess the clinical features and prognosis of 151 patients with extrahepatic metastases from primary hepatocellular carcinoma (HCC), and describe the treatment strategy for such patients. METHODS: After the diagnosis of HCC, all 995 consecutive HCC patients were followed up at regular intervals and 151 (15.2%) patients were found to have extrahepatic metastases at the initial diagnosis of primary HCC or developed such tumors during the follow-up period. We assessed their clinical features, prognosis, and treatment strategies. RESULTS: The most frequent site of extrahepatic metastases was the lungs (47%), followed by lymph nodes (45%), bones (37%), and adrenal glands (12%). The cumulative survival rates after the initial diagnosis of extrahepatic metastases at 6, 12, 24, and 36 mo were 44.1%, 21.7%, 14.2%, 7.1%, respectively. The median survival time was 4.9 mo (range, 0-37 mo). Fourteen patients (11%) died of extrahepatic HCC, others died of primary HCC or liver failure. CONCLUSION: The prognosis of HCC patients with extrahepatic metastases is poor. With regard to the cause of death, many patients would die of intrahepatic HCC and few of extrahepatic metastases. Although most of HCC patients with extrahepatic metastases should undergo treatment for the primary HCC mainly, treatment of extrahepatic metastases in selected HCC patients who have good hepatic reserve, intrahepatictumor stage (T0-T2), and are free of portal venous invasion may improve survival. | Kiminori Uka Hiroshi Aikata Shintaro Takaki Hiroo Shirakawa Soo Cheol Jeong Keitaro Yamashina Akira Hiramatsu Hideaki Kodama Shoichi Takahashi Kazuaki Chayama | 2007 | World Journal of Gastroenterology2007，13，3： | 44 |
| 2 | Patients with early recurrence of hepatocellular carcinoma have poor prognosis显示文摘BACKGROUND: Early recurrence(ER) after hepatic resection(HR) is a poor prognostic factor for patients with hepatocellular carcinoma(HCC). This study aimed to identify the clinicopathological features, outcomes, and risk factors for ER after HR for small HCC in order to clarify the reasons why ER is a worse recurrence pattern.METHODS: We retrospectively examined 130 patients who underwent HR for small HCC(≤30 mm). Recurrence was classified into ER(<2 years) and late recurrence(LR)(≥2 years). The clinicopathological features, outcomes, and risk factors for ER were analyzed by multivariate analysis.RESULTS: ER was observed in 39 patients(30.0%). The survival rate of the ER group was significantly lower than that of the LR group(P<0.005), and ER was an independent prognostic factor for poor survival(P=0.0001). The ER group had a significantly higher frequency(P=0.0039) and shorter interval(P=0.027) of development to carcinoma beyond the Milan criteria(DBMC) compared with the LR group, and ER was an independent risk factor for DBMC(P<0.0001). Multi-nodularity, non-simple nodular type, and microvascular invasion were independent predictors for ER(P=0.012, 0.010, and 0.019, respectively).CONCLUSIONS: ER was a highly malignant recurrence pattern associated with DBMC and subsequent poor survival after HR for small HCC. Multi-nodularity, non-simple nodular type, and microvascular invasion predict ER, and taking these factors into consideration may be useful for the decision of the treatment strategy for small HCC after HR. | Tomoki Kobayashi Hiroshi Aikata Tsuyoshi Kobayashi Hideki Ohdan Koji Arihiro Kazuaki Chayama | 2017 | Hepatobiliary & Pancreatic Diseases International2017，16，3： | 15 |
| 3 | Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases显示文摘The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC). Systemic gemcitabine chemotherapy seems effective in many cancers. We report the results of combination therapy with systemic gemcitabine, intra-arterial low-dose cisplatin and 5-FU (GEMFP). Seven patients with non-resectable advanced HCC were treated with GEMFP. One course of chemotherapy consisted of daily intra-arterial cisplatin (20 mg/body weight/hour on d 1, 10 mg/body weight per 0.5 h on d 2-5 and 8-12), followed by 5-FU (250 mg/body weight per 5 h on d 1-5 and 8-12) via an injection port. Gemcitabine at 1000 mg/m2 was administered intravenously at 0.5 h on d 1 and 8. The objective response was 57%. The response to GEMFP was as follows: complete response (no patients), partial response (four patients), stable disease (three patients), and progressive disease (no patients). The median survival period was 8 mo (range, 5-55). With regard to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 3 or 4 adverse reactions, seven (100%), seven, six (86%) and one (14%) patients developed leukopenia, neutropenia, thrombocytopenia and anemia, respectively. GEMFP may potentially be effective for non- resectable advanced HCC, but it has severe hematologic toxicity. | Kiminori Uka Hiroshi Aikata Shintaro Takaki Tomokazu Kawaoka Hiromi Saneto Daiki Miki Shoichi Takahashi Naoyuki Toyota Katsuhide Ito Kazuaki Chayama | 2008 | World Journal of Gastroenterology2008，14，16： | 4 |
| 4 | Effects of a 24-week course of interferon-αtherapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma显示文摘AIM:To assess whether a 24-wk course of interferon (IFN)could prevent hepatocellular carcinoma(HCC) recurrence and worsening of liver function in patients with hepatitis C virus(HCV)-infected patients after receiving curative treatment for primary HCC. METHODS:Outcomes in 42 patients with HCV infection treated with IFN-α,after curative treatment for primary HCC(IFN group),were compared with 42 matched curatively treated historical controls not given IFN(non- IFN group). RESULTS:Although the rate of initial recurrence did not differ significantly between IFN group and non-IFN group (0%,44%,61%,and 67% vs 4.8%,53%,81%,and 87% at 1,3,5,and 7 years,P=0.153,respectively), IFN group showed a lower rate than the non-IFN group for second recurrence(0%,10.4%,28%,and 35% vs 0%,30%,59%,and 66% at 1,3,5 and 7 years, P=0.022,respectively).Among the IFN group,patients with sustained virologic response(SVR)were less likely to have a second HCC recurrence than IFN patients without an SVR,or non-IFN patients.Multivariate analysis identified the lack of SVR as the only independent risk factor for a second recurrence,while SVR and Child-Pugh class A independently favored overall survival. CONCLUSION:Most intrahepatic recurrences of HCV- related HCC occurred during persistent viral infection. Eradication of HCV is essential for the prevention of HCC recurrence and improvement of survival. | Soo Cheol Jeong Hiroshi Aikata Yoshio Katamura Takahiro Azakami Tomokazu Kawaoka Hiromi Saneto Kiminori Uka Nami Mori Shintaro Takaki Hideaki Kodama Koji Waki Michio Imamura Hiroo Shirakawa Yoshiiku Kawakami Shoichi Takahashi Kazuaki Chayama | 2007 | World Journal of Gastroenterology2007，13，40： | 3 |
| 5 | Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma显示文摘AIM: To assess the efficacy of low-dose intermittent interferon (IFN) therapy in patients with hepatitis C virus (HCV)-related compensated cirrhosis who had received curative treatment for primary hepatocellular carcinoma (HCC). METHODS: We performed a prospective case controlled study. Sixteen patients received 3 MIU of natural IFN- alpha intramuscularly 3 times weekly for at least 48 wk (IFN group). They were compared with 16 matched historical controls (non-IFN group). RESULTS: The cumulative rate of first recurrence of HCC was not significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 68.6% vs 80% at 1- and 3-year, P = 0.157, respectively). The cumulative rate of second recurrence was not also significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 35.9% vs 67% at 1- and 3-year, P = 0.056, respectively). Although the difference in the Child-Pugh classification score between the groups at initial treatment of HCC was not signifi cant, the score was signifi cantly worse at the time of data analysis in the non-IFN group than IFN group (7.19 ± 1.42 vs 5.81 ± 0.75, P = 0.0008). The cumulative rate of deviation from objects of any treatment for recurrentHCC was also higher in the non-IFN group than IFN group (6.7% and 27% vs 0 and 0% at 1- and 3-year, P = 0.048, respectively). CONCLUSION: Low-dose intermittent IFN-alpha therapy for patients with HCV-related compensated cirrhosis after curative HCC treatment was effective by making patients tolerant to medical or surgical treatment for recurrent HCC in the later period of observation. | Soocheol Jeong Hiroshi Aikata Yoshio Katamura Takahiro Azakami Tomokazu Kawaoka Hiromi Saneto Kiminori Uka Nami Mori Shintaro Takaki Hideaki Kodama Koji Waki Michio Imamura Hiroo Shirakawa Yoshiiku Kawakami Shoichi Takahashi Kazuaki Chayama | 2007 | World Journal of Gastroenterology2007，13，39： | 2 |
| 6 | Impact of Pegylated Interferon Therapy on Outcomes of Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Hepatic Resection显示文摘 | Yoshisato Tanimoto MD Hirotaka Tashiro MD Hiroshi Aikata MD Hironobu Amano MD Akihiko Oshita MD Tsuyoshi Kobayashi MD Shintaro Kuroda MD Hirofumi Tazawa MD Shoichi Takahashi MD Toshiyuki Itamoto MD Kazuaki Chayama MD Hideki Ohdan MD | 2012 | Annals of Surgical Oncology2012，，2： | 2 |
| 7 | Telomere Reduction in Human Liver Tissues with Age and Chronic Inflammation显示文摘 | Hiroshi Aikata Hideki Takaishi Yoshiiku Kawakami Shoichi Takahashi Mikiya Kitamoto Toshio Nakanishi Yasuhiro Nakamura Fumio Shimamoto Goro Kajiyama Toshinori Ide | 2000 | Experimental Cell Research2000，，2： | 2 |
| 8 | Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis显示文摘 | Yoshio Katamura Hiroshi Aikata Shintaro Takaki Takahiro Azakami Tomokazu Kawaoka Koji Waki Akira Hiramatsu Yoshiiku Kawakami Shoichi Takahashi Masahiro Kenjo Naoyuki Toyota Katsuhide Ito Kazuaki Chayama | 2009 | Journal of Gastroenterology2009，，5： | 2 |
| 9 | Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma显示文摘 | Yohji Honda Tomoki Kimura Hiroshi Aikata Tomoki Kobayashi Takayuki Fukuhara Keiichi Masaki Takashi Nakahara Noriaki Naeshiro Atsushi Ono Daisuke Miyaki Yuko Nagaoki Tomokazu Kawaoka Shintaro Takaki Akira Hiramatsu Masaki Ishikawa Hideaki Kakizawa Masahiro | 2013 | J Gastroenterol Hepatol2013，，3： | 2 |
| 10 | Hypersensitivity Reactions to Transcatheter Chemoembolization with Cisplatin and Lipiodol Suspension for Unresectable Hepatocellular Carcinoma显示文摘 | Tomokazu Kawaoka Hiroshi Aikata Yoshio Katamura Shintaro Takaki Koji Waki Akira Hiramatsu Shoichi Takahashi Masashi Hieda Hideaki Kakizawa Kazuaki Chayama | 2010 | Journal of Vascular and Interventional Radiology2010，，8： | 1 |
| 11 | Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma显示文摘 | Kiminori Uka Hiroshi Aikata Shintaro Takaki Daiki Miki Tomokazu Kawaoka Soo Cheol Jeong Shoichi Takahashi Naoyuki Toyota Katsuhide Ito Kazuaki Chayama | 2007 | Journal of Gastroenterology2007，，10： | 1 |
| 12 | Telomere Reduction in Human Liver Tissues with Age and Chronic In? ammation显示文摘 | Aikata H Takaishi H Kawakami Y | 2000 | Exp Cell Res2000，256，2： | 1 |
| 13 | Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma显示文摘 | Katamura Y Aikata H Hashimoto Y | | 0，，10： | 1 |
| 14 | Genetics of IL28B and HCV--response to infection and treatment显示文摘 | Hayes CN Imamura M Aikata H | | 0，，7： | 1 |
| 15 | Circulating microRNA‐22 correlates with microRNA‐122 and represents viral replication and liver injury in patients with chronic hepatitis B显示文摘 | Keiko Arataki C. Nelson Hayes Sakura Akamatsu Rie Akiyama Hiromi Abe Masataka Tsuge Daiki Miki Hidenori Ochi Nobuhiko Hiraga Michio Imamura Shoichi Takahashi Hiroshi Aikata Tomokazu Kawaoka Hiroiku Kawakami Waka Ohishi Kazuaki Chayama | 2013 | J Med Virol2013，，5： | 1 |
| 16 | Combination of transcather arterial chemo-embolization using cisplatin lipiodol suspension and percutaneous enthaol injection for treatment of advanced small hepetocellular carcrinoma显示文摘 | Kamada K Kitamoto M Aikata H | 2002 | Am J Surg2002，184，： | 1 |
| 17 | Is small‐bowel capsule endoscopy effective for diagnosis of esophagogastric lesions related to portal hypertension?显示文摘 | Taiki Aoyama Shiro Oka Hiroshi Aikata Makoto Nakano Ikue Watari Noriaki Naeshiro Shigeto Yoshida Shinji Tanaka Kazuaki Chayama | 2014 | J Gastroenterol Hepatol2014，，3： | 1 |
| 18 | Efficacy of radiofrequency ablation for inital recurrent hepatocelluar carcinoma after curative treatment : Comparison with primary cases 显示文摘 | Fukuhara T Aikata H Hyogo lq | 2015 | Eur J Radiol2015，84，8： | 1 |
| 19 | Transarterial infusion che-motherapy using cisplatin-lipiodol suspension with or without em-bolization for unresectable hepatocellular carcinoma显示文摘 | Kawaoka T Aikata H Takaki S | 2009 | Cardiovasc lntervent Radiol2009，32，4： | 1 |
| 20 | Interleukin‐28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation显示文摘 | Tomokazu Kawaoka Shoichi Takahashi Shintaro Takaki Akira Hiramatsu Koji Waki Nobuhiko Hiraga Daiki Miki Masataka Tsuge Michio Imamura Yoshiiku Kawakami Hiroshi Aikata Hidenori Ochi Takashi Onoe Hirotaka Tashiro Hideki Ohdan Kazuaki Chayama | 2012 | Journal of Gastroenterology and Hepatology2012，，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员